MX2018000040A - Composiciones y métodos para utilizar cuerpos lamelares para propósitos terapéuticos. - Google Patents

Composiciones y métodos para utilizar cuerpos lamelares para propósitos terapéuticos.

Info

Publication number
MX2018000040A
MX2018000040A MX2018000040A MX2018000040A MX2018000040A MX 2018000040 A MX2018000040 A MX 2018000040A MX 2018000040 A MX2018000040 A MX 2018000040A MX 2018000040 A MX2018000040 A MX 2018000040A MX 2018000040 A MX2018000040 A MX 2018000040A
Authority
MX
Mexico
Prior art keywords
lamellar bodies
compositions
methods
therapeutic purposes
biofilm production
Prior art date
Application number
MX2018000040A
Other languages
English (en)
Inventor
Mclean Alec
Howard Lynsey
Kadioglu Aras
Winstanley Craig
Original Assignee
Lamellar Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamellar Biomedical Ltd filed Critical Lamellar Biomedical Ltd
Publication of MX2018000040A publication Critical patent/MX2018000040A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

Producción de biopelícula, que proporciona microbios con una comunidad estructurada de múltiples capas unida a una superficie y encerrada dentro de una matriz del material exopolimérico, se asocia con la virulencia de la infección favorecida en la expresión y puede limitar la respuesta del sistema inmunitario y/o la efectividad de los agentes terapéuticos. Se proporciona el uso de cuerpos lamelares para modular la detección de cuórum para inhibir o reducir la producción de la biopelícula y para el tratamiento de infecciones microbianas.
MX2018000040A 2015-06-23 2016-06-23 Composiciones y métodos para utilizar cuerpos lamelares para propósitos terapéuticos. MX2018000040A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1511058.8A GB201511058D0 (en) 2015-06-23 2015-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes
PCT/GB2016/051890 WO2016207645A1 (en) 2015-06-23 2016-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes

Publications (1)

Publication Number Publication Date
MX2018000040A true MX2018000040A (es) 2019-01-10

Family

ID=53784408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000040A MX2018000040A (es) 2015-06-23 2016-06-23 Composiciones y métodos para utilizar cuerpos lamelares para propósitos terapéuticos.

Country Status (24)

Country Link
US (1) US20180169145A1 (es)
EP (2) EP3626232A1 (es)
JP (1) JP2018518538A (es)
KR (1) KR20180036958A (es)
CN (1) CN107920994A (es)
AU (1) AU2016281764A1 (es)
BR (1) BR112017027899A2 (es)
CA (1) CA2990743A1 (es)
DK (1) DK3313377T3 (es)
ES (1) ES2754436T3 (es)
GB (1) GB201511058D0 (es)
HK (1) HK1248136A1 (es)
HR (1) HRP20192091T1 (es)
HU (1) HUE046510T2 (es)
IL (1) IL256498A (es)
LT (1) LT3313377T (es)
MX (1) MX2018000040A (es)
PH (1) PH12017502432A1 (es)
PL (1) PL3313377T3 (es)
PT (1) PT3313377T (es)
RS (1) RS59551B1 (es)
RU (1) RU2017145630A (es)
WO (1) WO2016207645A1 (es)
ZA (1) ZA201800372B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781123A1 (en) * 2018-04-17 2021-02-24 Lamellar Biomedical Limited Antifibrotic composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
AU2943389A (en) * 1988-01-13 1989-08-11 Upjohn Company, The Enhanced production of cellular proteins using butyrate
WO1991012026A1 (en) * 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
WO1998053800A1 (en) * 1997-05-29 1998-12-03 Applied Biotechnologies, Inc. Compositions and methods for preventing adhesion
GB9807298D0 (en) * 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
US7498292B2 (en) * 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
GB0322448D0 (en) * 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
CN1634358A (zh) * 2004-11-04 2005-07-06 杨雪 含抗微生物、抗病毒天然精油和磷脂类组合物
WO2008066631A2 (en) * 2006-10-27 2008-06-05 Athena Biotechnologies, Inc. Methods of disrupting quorum sensing to affect microbial population cell density
CN101903513B (zh) * 2007-01-12 2013-08-21 科罗拉多大学董事会法人 增强微生物对产生的有机化学物质的耐受性的组合物和方法
WO2014017233A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物用活性調節剤及び微生物の活性を調節する方法

Also Published As

Publication number Publication date
JP2018518538A (ja) 2018-07-12
HUE046510T2 (hu) 2020-03-30
CA2990743A1 (en) 2016-12-29
HRP20192091T1 (hr) 2020-02-21
GB201511058D0 (en) 2015-08-05
EP3313377A1 (en) 2018-05-02
RS59551B1 (sr) 2019-12-31
KR20180036958A (ko) 2018-04-10
LT3313377T (lt) 2019-11-25
EP3313377B1 (en) 2019-08-21
PH12017502432A1 (en) 2018-07-02
EP3626232A1 (en) 2020-03-25
AU2016281764A1 (en) 2018-01-25
ES2754436T3 (es) 2020-04-17
HK1248136A1 (zh) 2018-10-12
ZA201800372B (en) 2020-05-27
US20180169145A1 (en) 2018-06-21
PL3313377T3 (pl) 2020-01-31
RU2017145630A3 (es) 2019-07-24
IL256498A (en) 2018-02-28
WO2016207645A1 (en) 2016-12-29
CN107920994A (zh) 2018-04-17
PT3313377T (pt) 2019-10-31
BR112017027899A2 (pt) 2018-08-28
RU2017145630A (ru) 2019-07-23
DK3313377T3 (da) 2019-11-11

Similar Documents

Publication Publication Date Title
CL2015003120A1 (es) Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2021008036A (es) Bioplaguicidas para la enfermedad tizon tardio de la papa.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
NZ713621A (en) Compounds and methods of treating infections
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
IL271863B (en) Compounds and their use for the treatment of microbial infections
MX359104B (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
ZA202002093B (en) Antibacterial compounds
PH12016501988A1 (en) Antibacterial compounds
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
IT201700068009A1 (it) Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
HK1243951A1 (zh) 抗微生物組合和其在治療微生物感染中的用途
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
PH12017502432A1 (en) Compositions and methods for using lamellar bodies for therapeutic purposes
CL2015002759A1 (es) Métodos de tratamiento de infecciones en pacientes con sobrepeso y obesos usando antibióticos
PH12019502332A1 (en) Treatment of a bacterial vaginal infection
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
AR101538A1 (es) Cepas bacterianas que tienen actividad antimicrobiana y composiciones de biocontrol que las comprenden
MX2020001808A (es) Nuevos compuestos.
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections

Legal Events

Date Code Title Description
FG Grant or registration